Linda Tharby will retire as president and CEO of Mahwah-based KORU Medical Systems, effective June 30.
Its board of directors has appointed Adam Kalbermatten, currently chief commercial officer, as president and chief executive officer, effective March 15, and July 1, respectively.
Tharby, who spent five years in her role, will remain on the board and serve in an advisory capacity through the end of 2026 to support this leadership succession plan.
KORU is a leading medical technology company focused on the development, manufacturing, and commercialization of innovative, patient-centric, large-volume subcutaneous infusion solutions.
“Serving as Chief Executive Officer of KORU has been the highlight of my career, and I am incredibly proud of what our team has accomplished together,” Tharby said in a release.
“We have built a stronger, more scalable business with a clear strategy and a leadership position with significant potential in the subcutaneous drug delivery business.”
Under Tharby, KORU Medical doubled its recurring patient base to over 55,000 patients, expanding its international footprint and broadening the Freedom infusion platform beyond immunoglobulin to new drug classes.
The company achieved consistent revenue growth, achieved profitability, and established KORU Medical as a recognized market leader.
Kalbermatten joined KORU Medical in 2025 as Chief Commercial Officer, bringing more than 20 years of experience in the medical device and pharmaceutical industries. Before joining KORU, he served as Vice President and General Manager of Advanced Drug Delivery Systems at Becton Dickinson, where he led growth initiatives across the injectable drug-delivery platform.
